New FDA Chief Scott Gottlieb: Medication Reformer or Big Pharma Shill?
From the article:
Gottlieb's position has earned cautious approval from medical industry observers like Washington University associate professor Rachel Sachs, who wrote, "As someone who understands the drug development process from all sides, [Gottlieb] will be more informed. I'm going to wait to judge to see what policy decisions he comes to. Hopefully, he has the agency's best interest at heart." More significantly, the pharmaceutical industry has applauded his appointment, "We look forward to working with Dr. Gottlieb in his new role," said Stephen J. Ubl, president and CEO of the Pharmaceutical Research and Manufacturers of America.
Read more here!bioethics fda health care finance health care reform health law policy rachel sachs regulation research